Skip to main content
MDCX
NASDAQ Life Sciences

Medicus Pharma 提交优化的2期方案用于Teverelix，目标20亿美元市场，采用资本高效的设计

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$0.451
Mkt Cap
$17.595M
52W Low
$0.37
52W High
$8.94
Market data snapshot near publication time

summarizeSummary

Medicus Pharma 已向FDA提交了用于其实验性药物Teverelix的优化的2期研究方案，用于治疗急性尿潴留。这一改进的设计旨在将研究规模减少三分之二，并大幅降低整体开发成本，从而加速产品的商业化进程，瞄准估计的20亿美元市场。考虑到该公司最近的“持续经营”警告和对稀释性资本增发的依赖，这一发展尤其重要，因为它表明了公司在资本效率和加速开发方面的战略重点。全球公认的泌尿学专家作为首席研究员的参与进一步加强了该方案。交易者将关注FDA对该方案的接受和研究的启动，随后是中期分析结果。

在该公告发布时，MDCX的交易价格为$0.45，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1759.5万。 52周交易区间为$0.37至$8.94。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed MDCX - Latest Insights

MDCX
Apr 24, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
9
Medicus Pharma Faces Nasdaq Delisting, Discloses $11.5M Raised in Highly Dilutive ATM Program
Sentiment: Negative
View Wiseek Article
MDCX
Apr 23, 2026, 5:10 PM EDT
Filing Type: 424B3
Importance Score:
9
Medicus Pharma Expands At-The-Market Offering to $50M, Signaling Extreme Dilution Risk Amidst Financial Distress
Sentiment: Negative
View Wiseek Article
MDCX
Apr 21, 2026, 6:01 AM EDT
Filing Type: PRE 14A
Importance Score:
8
Medicus Pharma Proposes Reverse Stock Split Up to 1:50 to Avoid Nasdaq Delisting
Sentiment: Negative
View Wiseek Article
MDCX
Apr 06, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Medicus Pharma Submits Optimized Phase 2 Protocol for Teverelix, Targeting $2B Market with Capital-Efficient Design
Sentiment: Positive
View Wiseek Article
MDCX
Mar 26, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Medicus Pharma's SkinJect Phase 2 Hits 80% ORR, Aims to Reduce Skin Cancer Surgeries
Sentiment: Positive
View Wiseek Article
MDCX
Mar 25, 2026, 4:49 PM EDT
Filing Type: 424B3
Importance Score:
8
Medicus Pharma Discloses Going Concern Warning, Reports Heavy Dilution and Positive Phase 2 Data in Annual Filing
Sentiment: Negative
View Wiseek Article
MDCX
Mar 25, 2026, 4:30 PM EDT
Source: Access Newswire
Importance Score:
7
Medicus Pharma Reports Positive SkinJect Phase 2 Data, Secures $31.9M Capital
Sentiment: Positive
View Wiseek Article
MDCX
Mar 25, 2026, 4:08 PM EDT
Filing Type: 10-K
Importance Score:
9
Medicus Pharma Faces Critical Going Concern Warning Amidst Massive Dilution and Director's Large Selling Plan
Sentiment: Negative
View Wiseek Article
MDCX
Mar 06, 2026, 4:58 PM EST
Filing Type: 424B3
Importance Score:
8
Medicus Pharma Secures $3.85M Through Equity Sales to Yorkville, Reducing Debt and Extending Runway
Sentiment: Neutral
View Wiseek Article
MDCX
Mar 06, 2026, 4:57 PM EST
Filing Type: 424B3
Importance Score:
8
Medicus Pharma Secures $3.85M Through Equity Sales, Prepaying Debt
Sentiment: Neutral
View Wiseek Article